Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if translocator protein total distribution volume (TSPO VT) is elevated in major depressive disorder that is not responding to medication and if adding minocycline can affect TSPO VT. Many remain treatment resistant with common antidepressant treatments and the investigators think it may be due to poor targeting of brain pathologies.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre for Addiction and Mental Health
• Treatments: Anti-Inflammatory Agents; Celecoxib; Minocycline

Criteria

Group 1 - Current major depressive episode (MDE) secondary to MDD

Inclusion Criteria:

• good physical health with no active medical conditions

• non-cigarette smoking

• no past or current substance abuse or dependence

• negative urine pregnancy test at screening and scan days (for women)

• primary diagnosis of current major depressive episode (MDE) and major depressive disorder (MDD) verified by SCID for DSM IV

• score greater than 19 on the 17 item HDRS

• non-response to a clinical trial of at least one antidepressant given at appropriate clinical dose

• willing to take medication for the duration of the trial and has previously taken antidepressants for the duration of the trial

• presently taking an antidepressant at a standard clinical dose.

Exclusion Criteria:

• history of neurological illness or autoimmune disorders

• never taken a tricyclic antidepressant or an antidepressant that raises norepinephrine

• received treatment with electroconvulsive therapy or mechanical brain stimulation in the previous 6 months

• currently taking medication contraindicated or that may possibly interact with either minocycline or celecoxib

• known intolerance or allergy to minocycline, other tetracyclines, sulfonamides or NSAIDs

• taken diazepam or other benzodiazepine use within the past month, except for lorazepam and clonazepam

• use of anti-inflammatory drugs or tetracyclines lasting ≥1 week within the past month

• history of severe hepatic or renal insufficiency, asthma, allergies, gastrointestinal disease, ischemic heart disease, cerebrovascular disease or congestive heart failure

• lactose intolerance

Group 2 - Healthy Controls - Phase 1 (baseline scan) only

Inclusion criteria:

• score below 8 on the 17 item HDRS

• good physical health

• non-cigarette smoking

• negative urine pregnancy test at screening and scan days (for women)

• negative urine screen for drugs of abuse

Exclusion criteria:

• past or current diagnosis of axis I or axis II disorder as determined by the SCID I and SCID II for DSM IV

• history of psychotropic medication use

• history of neurological illness or autoimmune disorder